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Dengue virus (DENV) is the most common and widespread arboviral infection worldwide.
Though all four DENV serotypes cocirculate in nature, the clinicopathological framework
of these serotypes is undefined in Pakistan. A cross-sectional, observational study was
performed to document the circulation of various arboviruses in the Sindh region of
Pakistan. Here we describe a population of patients diagnosed with DENV spanning
a 2-year period. This study used an orthogonal system of NS1 antigen ELISA followed
by RT-PCR for DENV detection and subtyping. A total of 168 NS1 positive patients were
evaluated of which 91 patients were serotyped via RT-PCR. There was no significant
difference between sex or age for infection risk and peak transmission occurred during
the Autumn months. DENV2 was the most common serotype followed by DENV1
then DENV3, then DENV4. The data show that DENV1 patients were more likely to
have abnormal liver function tests; DENV2 infected patients were more likely to exhibit
arthralgia and neurological symptoms; DENV3 patients were more likely to complain
of burning micturition and have elevated lymphocyte counts and low hematocrit; and
DENV4 patients were more likely to report headaches and rash. Notably, no dengue
hemorrhagic fever or other manifestations of severe dengue fever were present in patients
with primary or secondary infections. We were able to identify significantly more NS1
antigen positive patients than RT-PCR. This study demonstrates that all four DENV
serotypes are co-circulating and co-infecting in Pakistan.
Keywords: dengue, co-infection, co-circulation, hemorrhagic fever, secondary infection

INTRODUCTION
Dengue virus (DENV) is the most common and widespread arboviral infection on Earth (1).
DENV is a flavivirus composed of four antigenically distinct serotypes that causes a spectrum
of disease ranging from mild febrile illness to death. Antibody-dependent enhancement during
secondary DENV infections can exacerbate disease leading to dengue shock syndrome (DSS),
dengue hemorrhagic fever (DHF), and dengue break-bone fever (2). Though these viruses occupy
the same ecological niche, co-infections are rarely reported.
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disease, it was necessary to classify RT-PCR + patients by their
infection status. Primary infection was defined as NS1 AND RTPCR positive but negative for neutralizing IgG by PRNT using
patient specimen collected upon study enrollment. Secondary
infection was defined as NS1 positive AND RT-PCR positive
AND neutralizing IgG positive by PRNT using patient specimen
collected upon study enrollment. Co-infections were defined as
NS1 AND RT-PCR positive for 2 DENV serotypes but negative
for neutralizing IgG by PRNT using patient specimen collected
upon study enrollment.

DENV is endemic to Pakistan along with West Nile virus
(WNV), Japanese encephalitis virus (JEV), and Chikungunya
virus (CHIKV) (3–5). These viruses have overlapping syndromes
which complicates diagnosis leading to poorly defined
epidemiology. Serological diagnosis is difficult due to antigenic
cross reactivity of flaviviruses (6). Nucleic acid detection is
equally as difficult due to the short duration of detectable
viremia (7). Fortunately, advances in flaviviral diagnostics have
significantly improved accurate and timely diagnosis which can
have a direct and positive effect on patient care. For instance,
several ELISA and lateral flow assays are commercially available
that can simultaneously detect DENV antigen, IgM and IgG
antibodies (8–11). This can help health care providers easily
distinguish between early, primary, and secondary infections.
Though all four DENV serotypes cocirculate in nature,
the clinical manifestations of these serotypes are undefined
in Pakistan as well as the contribution of secondary and coinfections on the presentation of severe manifestations of disease.
Here we describe a population of patients diagnosed with
DENV over a 2-year period. Patients were divided according to
their infecting serotype to document serotype-associated clinical
features that might help differentiate one serotype from another
in a primary health care setting.

Serology
Primary DENV screening in patients was performed using
a commercial ELISA (Panbio Dengue Early Rapid Test
NS1 antigen capture test (Alere, Waltham, MA), following
manufacturer’s instructions. IgM ELISA was performed to
rule out co-infection with WNV, JEV, CHIKV, and ZIKV
with commercially purchased IgM ELISA assays including
CHIKjj Detect, JE Detect, ZIKV Detect all from InBios
International (Seattle, USA) per manufacturer’s instructions.
Plaque reduction neutralization testing (PRNT) was performed
on all RT-PCR + patients as described elsewhere to determine
if patients had previous DENV exposure (4, 12). Briefly,
100 infectious units (i.u.) of virus (calculated from stock
virus titer) in PBS were incubated for 1 h at 37◦ C with
1:10 dilution of subject serum. Assay controls included 100
i.u. of virus in PBS, 100 i.u. of virus with 1:10 dilution
of positive control serum, and a mock infected control
consisting of PBS. Cells with inoculum were incubated at
37◦ C for 1 h after which the inoculum was removed and
an overlay consisting of MEM with 10% FBS and 0.5%
methylcellulose. Assays were incubated 3–7 days, depending on
serotype, at 37◦ C after which monolayers were stained with
Coomassie blue.
Viruses used included: DENV-1 (TS-SMAN), DENV-2
(NGC), DENV-3 (H87), and DENV-4 (H241). Viruses were
obtained from BEI Resources and expanded once in Vero E6
cells. Patients were classified has having prior DENV exposure
when there was neutralization of at least 80% at the 1:10 serum
dilution. Specimens that neutralized more than 1 serotype were
diluted out by 4-fold dilutions. The serotype with the most
neutralization at the greatest dilution was identified as the
infecting serotype.

METHODS
Ethics Statement
Adult participants or parents/legal guardians of minors were
enrolled under informed consent procedures which were
reviewed and approved by the Ethics Review Committee at
Aga Khan University (#3183-PAT-ERC-14) and the Institutional
Review Board at the University of Florida (#201500908). All
enrolled subjects gave written informed consent in accordance
with the Declaration of Helsinki.

Patient Samples
A cross-sectional, observational study was performed to
document the circulation of various arboviruses in the Sindh
region of Pakistan spanning 2015–2017 (4). Patients presenting
with the CDC clinical description of arboviral disease including
findings of rash, headache, arthralgia, myalgia, gastro-intestinal
distress, acute hemorrhagic fever, acute flaccid paralysis,
encephalitis, meningitis, and/or unexplained fever were recruited
(4). Patients younger than 10 and older than 90 years of age
were excluded. In total, 997 patients were enrolled, and clinical
and demographic information was recorded. All enrolled patients
provided a serum specimen which was screened for DENV NS1
antigen. 168 NS1 positive patients were evaluated for DENV
serotype via RT-PCR.

Nucleic Acid Tests
DENV primers and probes from the CDC RT-PCR assay were
used to detect the NS5, envelope, or prM protein depending
on serotype (4, 13). Briefly, RNA was isolated from human
serum samples using a commercial viral RNA extraction kit
(QIAamp viral RNA kit, Qiagen, Valencia, CA). RNA was
reverse transcribed to cDNA (iScript cDNA Synthesis Kit, BioRad, Hercules, California) and real-time PCR was performed
using a commercial master mix (BioRad iTaq Universal Probes
Supermix, BioRad, Hercules, CA, USA) and a commercial realtime PCR machine (BioRad CFX 96, BioRad) (4).

Case Definitions
All 4 DENV serotypes co-circulate in Pakistna and since
secondary and co-infections can cause more severe forms of
Abbreviations: ALT, Alanine transaminase; AST, Aspartate transaminase; CHIKV,
Chikungunya virus; DENV, Dengue virus; DHF, Dengue hemorrhagic fever; DSS,
Dengue shock syndrome; JEV, Japanese encephalitis virus; PRNT, Plaque reduction
neutralization test; WNV, West Nile virus; ZIKV, Zika virus.
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(Figure 1). A small number of patients were enrolled in Karachi
from individuals visiting from other regions such as the Western
province of Balochistan and the area around Lahore (Figure 1).
These cases occurred throughout the year irrespective of holidays
or festivals. All serotypes of DENV were identified year-round
with the majority of cases identified during the autumn months
(Figure 2). The average age of patients was 33 years and an equal
proportion of males and females were observed (Figure 3). There
was no significant difference between the serotypes for sex or age
(Figure 3). Of the 168 NS1 positive patients, 91 were serotyped
via RT-PCR. The remaining 77 patients were negative for all 4
DENV serotypes via RT-PCR and subtyping via plaque reduction
neutralization test was performed. However, serological crossreactivity prevented diagnosis thus, these patients were excluded
from the analysis. DENV2 (n = 59) was the most commonly
identified serotype by RT-PCR closely followed by DENV1 (n =
23). DENV3 was identified in 15 patients and DENV4 identified
in 7 patients. All RT-PCR positive patients were also negative
via IGM ELISA for JEV, WNV, CHIKV, and Zika viruses (data
not shown).
Of the 23 DENV1 subtyped patients, 14 were RT-PCR positive
for a second DENV serotype and 1 was identified as a secondary
infection (Table S1). Of the 59 patients that were RT-PCR
positive for DENV2, 12 had co-infections and 5 had secondary
infections (Table S1). Of 12 patients RT-PCR positive for DENV
3, 2 were also positive for DENV 1 co-infections and 1 patient
was positive for secondary DENV infection (Table S1). Seven
individuals were positive for DENV4 via RT-PCR of which one
patient was co-infected with DENV2 and another patient was
positive for a secondary DENV infection (Table S1).

FIGURE 1 | The locations of subjects infected with dengue virus during
2015–2017. The majority of cases were identified from Karachi.

Statistical Analysis
RT-PCR-positive patients were divided into 3 groups for
statistical analysis which included primary infection, coinfection, and secondary infection per the case definitions above.
We did not include patients with co-infections or secondary
infections in the primary analysis because research has shown
that these patients can have more severe manifestations of disease
than patients with a primary infection with a single serotype
(2, 14, 15). Clinical laboratory values were compared against the
normal reference range for the appropriate sex as needed (i.e.,
hematocrit). Statistical analyses were performed on clinical data
using MedCalc version 17.9.7 – 64-bit. Logistic regression for
dichotomous independent variables were performed. Odds ratios
were calculated with 95% confidence intervals. Ratios with a p
< 0.05 were considered significant. When comparing serotypes
with each other in respect to variables such as sex ratios, or
age distribution, an ANOVA with Laverne’s test, Tukey-Kramer
post-hoc and Chi square for normal distribution was performed.
When appropriate, pairwise comparisons were performed with a
Student’s T-test.

Clinical Manifestations
Temperature, heart rate, and blood pressure readings
were recorded upon enrollment. There were no significant
manifestations for any of the serotypes (Table 1). Most patients
from all DENV serotypes exhibited mean heart rates that were
within the normal range of 60–100 beats per minute with no
significant difference between serotypes (Table 1). Average blood
pressure readings were within the normal range and <20% of
patients (for all serotypes) exhibited abnormal readings. Average
temperatures for DENV1 and DENV2 were 37.4 and 37.5◦ C,
respectively (Table 1). Average temperatures for DENV3 and
DENV4 were higher with average enrollment temperatures
recorded at 38.0 and 38.2◦ C, respectively, with no significant
difference between serotypes (Table 1).
We performed logistic regression to obtain odds ratios for
a series of clinical hematological profiles commonly evaluated
upon admission to hospital. Over 60% of patients infected with
DENV1 exhibited elevated AST and ALT (Table 2). DENV1
patients were 2.0 times more likely to have elevated AST and
1.86 times more likely to have elevated ALT when compared with
the other 3 serotypes (Table 2). Total lymphocyte counts were
elevated in many patients however, DENV-3 infected individuals
were 2.89 times more likely to exhibit elevated lymphocyte
counts (Table 2). Thrombocytopenia is a common sign of DENV
infection which was reported for the majority of patients for all
serotypes though 100% of DENV1 and 80% of DENV4 infected

RESULTS
Patient Characteristics
A total of 168 NS1 positive patients were identified out of 997
subjects recruited from the Sindh province of Pakistan during
2015–2017. The vast majority of these 168 patients were recruited
from Karachi, the most populous city in the region. Patients
were also recruited from Mirpurkhas, Larkana, and Sukkur
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FIGURE 2 | The sustained co-circulation of 4 dengue serotypes in the Sindh region of Pakistan 2015–2017. Data presented represents all RT-PCR positive samples
including co-infections and secondary infections.

FIGURE 3 | Age and gender of individuals infected with dengue virus. The data represents all primary and secondary infections.
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patients exhibited low platelet counts and were at least 2.0 times
more likely than any other serotype to have thrombocytopenia
than the other serotypes (Table 2). Low hemoglobin counts were
reported for 16% of DENV2 infected patients and 14% of DENV3
infected patients but not in DENV1 or DENV4 patients (Table 2).
Below normal hematocrit levels were reported for 62% of DENV2
patients and 75% of DENV3 patients while no DENV1 and only
1 DENV4 infected patient had below normal hematocrit levels
(Table 2). When compared with the other serotypes, DENV3
patients were twice as likely to exhibit low hematocrit levels
(Table 2).
We performed logistic regression to obtain odds ratios for
a series of common DENV-associated symptoms in order to
determine if there were serotype-associated symptoms. Myalgia
was a common symptom of all serotypes with at least 45% of
patients reporting body aches (Table 3). Nausea and vomiting
were also common complaints with at least 62% of all patients, for
all serotypes, reporting these symptoms (Table 3). Eye pain was
rarely reported with only 7% of DENV2 patients complaining of
this symptom (Table 3). Overall, at least 58% of all patients were
given a provisional diagnosis of dengue fever with 75% of DENV1
patients obtaining this diagnosis (Table 3). For patients without

a provisional diagnosis of dengue fever, antibiotics were usually
prescribed (P = 0.0007) (Table 3).
The data indicates that patients with DENV1 infections were
less likely to report dengue-associated symptoms that any other
serotype. These patients had fewer complaints of arthralgia,
myalgia, rash, nausea, and eye pain (Table 3). These patients
were also significantly less likely to have a fever >38◦ C (P =
0.0261) (Table 3). Patients with DENV2 infections were 4.0 times
more likely to complain of arthralgia than the other serotypes
(Table 3). DENV2 patients were also 3.1 times more likely to
exhibit neurological symptoms including, altered mental status,
confusion, acute disseminated encephalomyelitis, or encephalitis
(Table 3). Patients with DENV3 infections were unlikely to
complain of arthralgia or other DENV-associated symptoms
(Table 3). These patients were 2.28 times more likely to complain
of burning micturition and 2.78 times more likely to have
a fever >38.5◦ C than the other serotypes (Table 3). Nearly
80% of patients with DENV4 infection were most likely to
exhibit dengue-like symptoms with patients being 6.78, 4.25,
and 4.3 time more likely to report headache, rash, and nausea,
respectively (Table 3).

Co-infections
Co-infections of 2 different DENV serotypes were detected by
RT-PCR in 14 individuals (Table S1). We performed logistic
regression to obtain odds ratios, comparing these patients
with all patients with primary infections. Research has shown
that co-infections can produce more severe manifestations
of disease (15). Thus, our goal was to determine if there
were any clinical features that might be associated with
infection with more than one DENV serotype. For our patients,
1 individual was co-infected with DENV serotypes 2 and
4. This patient had a fever of 39.4◦ C and hemorrhagic
manifestations. This individual developed acute disseminated
encephalomyelitis (ADEM). Three patients were co-infected

TABLE 1 | Vital statistics for patients with primary DENV infections.
Dengue 1

Dengue 2

Dengue 3

Dengue 4

97 (72–140)

100 (79–138)

Heart rate (bpm)

98 (56–133)

94 (58–152)

Systolic (mmHg)

122 (92–160)

118 (88–176) 115 (100–134) 118 (105–122)

Diastolic (mmHg)
Temperature (◦ C)
Respirations (bpm)

81 (55–112)

71 (32–92)

71 (56–83)

69 (54–84)

37.4 (36.4–38) 37.5 (36–40.5) 38 (36.5–39) 38.2 (38–38.6)
20 (17-22)

20.3 (17-27)

21 (20–24)

20 (18–22)

These patients were NS1 and RT–PCR positive for only one serotype and negative for
DENV neutralizing antibodies via PRNT.

TABLE 2 | Hematological profiles for patients with primary DENV infections.
Dengue 1
Mean (range)

OR (95% CI)

N (%)
AST (IU/L)

228 (59–406)
101 (20–247)

2.0 (0.19 20.14)

41 (12.9–52.7)

1.86 (0.38–8.98)

46.5 (12-133)

1.39 (0.3–6.41)
546E+006

146 (16–751)
30 (4–55.5)
119 (19–330)

7.14E−009

OR (95% CI)

114 (41–288)

Mean (range)

OR (95% CI)

N (%)
0.83 (0.12–5.47) Sample size too small

0.83 (0.25–2.72)

83.3 (28–277)

0.75 (0.17–3.29)

4 (33%)
0.56 (0.2–1.56)

27.1 (8.2–48.1) 2.89 (0.7–11.87)
9 (75%)

370E+015

134 (3–258)

0.94 (0.24–3.57)

13.5 (9.2–17.4) 1.81 (0.33–9.89) 13.5 (10.5–18.1) 1.43 (0.25–8.18)
2 (14%)

10 (62%)

3 (75%)

1.0 (0.12–7.81)

15.8 (3.5–24.1)

0.51 (0.07–3.27)

1 (20%)

8 (67%)

6 (16%)

86.2 (28–221)
1 (16.6%)

44.8 (36–48.2) 0.10 0.009–1.09 39.2 (32.7–46.9) 1.04 (0.23–4.7) 37.5 (31.4–42.8) 2.0 (0.18–22.05)
0 (0%)

Dengue 4

6 (50%)

23 (57%)

0 (0%)
Hematocrit

0.75 (0.13–4.09)

19 (46%)

8 (100%)
Hemoglobin (gm/dL) 15.4 (12.2–17.2)

139 (27-570)

Mean (range)
N (%)

11 (48%)

5 (62%)
Platelets (109 /L)

OR (95% CI)

12 (75%)

5 (62%)
TLC (109 /L)

Mean (range)

Dengue 3

N (%)

6 (86%)
ALT (IU/L)

Dengue 2

114 (43–204)

2.0 (0.2–19.09)

4 (80%)
13.8 (12.1–14.8)

7.14E−009

0 (0%)
40.2 (36.6–42.6)

629E+006

1 (25%)

These patients were NS1 and RT-PCR positive for only one serotype and negative for DENV neutralizing antibodies via PRNT. Bold font indicates statistical significance. OR, odds ratio;
CI, confidence interval; N, number of patients.
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TABLE 3 | Symptoms for patients with primary DENV infections.
Dengue 1

Dengue 2

Dengue 3

Dengue 4

OR (95% CI)

OR (95% CI)

OR (95% CI)

OR (95% CI)

N (%)

N (%)

N (%)

N (%)

0.0

4.0 (0.45–35.35)

2.34E−009

2.33 (0.22–24.4)

0

6 (14.2%)

0

1 (20%)

Myalgia

1.11 (0.25–4.84)

0.76 (0.28–2.05)

1.11 (0.31–3.89)

1.71 (0.26–10.93)

4 (50%)

19 (45.2%)

6 (50%)

3 (60%)

Headache

0.45 (0.06–2.91)

1.02 (0.37–2.8)

0.69 (0.15–3.09)

6.78 (0.71–64.42)

2 (25%)

17 (40.4%)

4 (33.3%)

4 (80%)

Rash

0.74 (0.08–6.82)

0.59 (0.15–2.28)

1.10 (0.2–5.99)

4.25 (0.61–29.520

1 (12.5%)

5 (12%)

2 (16.6%)

2 (40%)

Hemorrhagic manifestations

1.63 (0.31–10.75)

1.23 (0.33–4.61)

0.90 (0.17–4.76)

6.78E−009

2 (25%)

8 (19%)

2 (16.6%)

0

Fever ≥38◦ C

0.08 (0.01–0.75)

1.50 (0.54–4.15)

0.92 (0.24–3.390

618E+006

1 (12.5%)

23 (54.7%)

6 (50%)

5 (100%)

Nausea/vomiting

0.62 (0.13–2.89)

1.32 (0.44–3.92)

0.75 (0.19–2.86)

4.3 (0.23–78.63)

5 (62.5%)

31 (73.8)

8 (66.6%)

4 (80%)

Burning micturition

0.79 (0.08–7.25)

0.54 (0.13–2.09

2.28 (0.49–10.53)

1.47 (0.14–14.72)

Arthralgia

Neurologic symptoms
Dengue fever diagnosis

1 (12.5%)

5 (12%)

3 (25%)

1 (20%)

2.37E−009

3.1 (0.61–15.88)

1.02 (0.19–5.47)

6.92E−009

0

9 (21.4%)

2 (16.6%)

0

1.62 (0.27 to 9.49)

0.96 (0.33–2.8)

0.87 (0.22–3.38)

0.73 (0.08–6.58)

Antibiotics prescribed
Eye pain
Fever ≥38.5◦ C

6 (75%)

27 (62.4%)

7 (58.3%)

3 (60%)

0.40 (0.07–2.15)

1.42 (0.50–4.03)

1.13 (0.3–4.2)

0.88 (0.13–5.670

2 (25%)

18 (42.8%)

5 (41.6%)

2 (40%)

0.0

204E+006

6.88E−009

0.0

0

3 (7%)

0

0

1.83E−009

0.91 (0.26–2.19)

2.78 (0.7–9.1)

1.55 (0.53–22.76)

0

12 (26.2%)

6 (50%)

2 (40%)

Logistic analysis was performed in which a single serotype was compared against the other serotypes. These patients were NS1 and RT-PCR positive for only one serotype and negative
for DENV neutralizing antibodies via PRNT. Bold font indicates statistical significance. OR, odds ratio; CI, confidence interval; N, number of patients.

titers of neutralizing antibodies to DENV2. Five individuals with
active DENV2 infections had high neutralizing titers against
DENV1. One patient with an active DENV3 infection had high
titers of neutralizing antibodies against DENV2. One individual
with an active DENV4 infection had previous exposure to
DENV1. None of the patients with secondary infection exhibited
symptoms consistent with DHF or DSS in fact, these patients
were indistinguishable from patents with primary infections
of any serotype on the basis of their clinical manifestations
(Tables 3, 4).

with DENV serotypes 2 and 3 and 10 patients were coinfected with DENV1 and DENV2 (Table S1). These patients had
relatively mild manifestations of dengue fever complaining of
headache, myalgia, and nausea. Patients with co-infections were
indistinguishable from patients with a single infection on the
basis of their clinical manifestations (Table 4). Overall, patients
with co-infections exhibited the same clinical profiles as patients
infected with a single serotype (Table 4). Co-infected patients
were significantly less likely to have thrombocytopenia or low
hematocrit levels than patients infected with a single serotype
(Table 4).

DISCUSSION

Secondary Infections

Dengue fever has been described in historical records since
922 A.D. as a self-limiting febrile illness punctuated by joint
pain and rash (17, 18). However, it was not until 1966 that
DENV emerged in Pakistan where it was reported to cause nonspecific febrile illness accompanied by gastrointestinal symptoms
(19). DENV was not reported again in Pakistan until 1994 in
Karachi where DENV1 and DENV2 were identified during a
major outbreak (20, 21). In 2005, DENV3 was identified during
an outbreak of DHF in Karachi (22, 23). By 2008, all 4 serotypes
had been identified in Pakistan (24).

We performed logistic regression to obtain odds ratios
comparing individuals with secondary DENV infections with all
individuals with primary infections. Our goal was to identify
any significant clinical features that might be associated with
secondary infections. Secondary DENV infection commonly
result in more sever disease including DHF and DSS (2, 14–
16). All RT-PCR positive serum was used for PRNT assay
against the 3 respective RT-PCR negative serotypes. Secondary
DENV infections were identified in 8 individuals by PRNT
(Table S1). One patient PCR positive for DENV1 had high
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We identified co-infections of two DENV serotypes which,
according to the literature, should have resulted in more
severe manifestations of disease (18, 25–27). Our data show
that only a single co-infection of DENV2 and DENV4 caused
severe disease which appears to agree with other reports from
India (18). Patients co-infected with DENV1 and DENV2
were symptomatically indistinguishable from patients infected
with a single serotype. This also agrees with other reports
that DENV1 co-infections do not result in severe forms of
dengue fever (18). The window of detectable viremia via RTPCR is 3–5 days. While it is possible that these patients were
infected on separate occasions over a short duration of time
to be detected via RT-PCR. These patients would systemically
and immunologically progress as a co-infection from a single
inoculation. The scenario that these patients were infected by
a co-infected mosquito is much more likely as co-infection of
vectors has been reported for DENV in multiple lab and field
studies (28–30).
A noteworthy finding was the absence of DHF or other
manifestations of severe dengue fever in our patients with
secondary infections and all but 1 of the co-infected. A recent
review of DENV infection in India showed that the overall
percentage of severe DENV infection was 28.9% of all cases
(31). DHF and severe DENV are reported at rates of 0.5–
1% globally (32). The presence of a DENV-resistance gene has
been proposed since numerous reports document the absence of
DHF and severe DENV in persons of African descent, especially
populations in Haiti (33–36). However, these theories have never
been substantiated and the mechanism for this phenomenon
are unknown. The relative absence of DHF in Pakistan and
wide-spread occurrence of DHF in India reflect studies of the
Caribbean islands and raises the question if there is a genetic or
immunological factor in the population of Pakistan that confers
resistance to severe DENV (2, 34–36).
The role of T cells in viral hemorrhagic fevers has not been
characterized and the protective or pathogenic contribution of T
cells is unclear (37). However, the protective role of memory CD8
cells presenting cross-reactive epitopes has been shown to protect
against secondary DENV infections in endemic areas (38, 39).
In addition, sequential flaviviral infections can also confer crossprotection against primary or secondary DENV infections (40).
Another plausible explanation could be that persistent
exposure to co-circulating viral pathogens (DENV1–4, WNV,
JEV) has corrupted the normal immune defenses of this
population. Memory CD8 T cells have been shown to respond
to antigens, independent of T cell receptors to pathogens that
cause inflammation (41–43). This allows memory CD8 cells to
contribute to the innate immune response by detecting changes
in cytokine production and eliciting a defensive response (44–
46). However, during chronic viral infections, CD8 cells become
exhausted and lose their self-renewal properties and over time,
become depleted (41, 47, 48). Exhausted CD8 cells also lose
their ability to produce interferon-γ when exposed to cognate
antigens (49, 50). It is theorized that this loss of antigenic
recognition could be immunopathogenic and contribute to
sustained chronic viral infections (41). It could be that CD8
exhaustion if contributing to the lack of enhanced immune

TABLE 4 | Symptoms and hematological profiles for patients with DENV
co-infections and secondary infections.

Arthralgia

Co-infection

Secondary infection

OR (95% CI)

OR (95% CI)

N (%)

N (%)

2.85 (0.72–11.31)

1.42 (0.14–13.65)

4 (26.6%)

1 (12.5%)

Myalgia

0.36 (0.1–1.24)

1.45 (0.3–7.02)

4 (26.6%)

4 (50%)

Headache

0.88 (0.28–2.73)

3.70 (0.66–20.49)

6 (40%)

5 (62.5%)

Rash

0.77 (0.15–3.92)

0.90 (0.09–8.3)

2 (13.3%)

1 (12.5%)

Hemorrhagic manifestations

0.30 (0.036–2.54)

6.72E−009

1 (6.6%)

0

Fever ≥38◦ C

0.77 (0.25–2.33)

1.03 (0.27–3.92)

10 (71.4%)

7 (87.5%)

Nausea/vomiting

0.50 (0.16–1.56)

0.79 0.13–4.68

Burning micturition

8 (53.3%)

5 (62.5%)

2.23E−009

6.97E−009

0

1 (12.5%)

Neurologic symptoms

0.34 (0.04–2.84)

0.84 (0.09–7.76)

1 (6.6%)

1 (12.5%)

Dengue fever diagnosis

1.12 (0.34–3.64)

3.07 (0.34–27.11)

9 (60%)

5 (62.5%)

Antibiotics prescribed

1.71 (0.56–5.18)

1.3 (0.31–5.34)

Eye pain

6 (40%)

0

6.81E−009

3.55 0.31–39.70

0

1 (12.5%)

ALT

1.25 (0.29–5.280

5.0 (0.53–46.35)

3 (20%)

2 (25%)

AST

0.22 (0.06–0.83)

2.21E−010

5 (33.3%)

5 (62.5%)

Systolic

0.51 (0.05–4.41)

7.15E−009

1 (6.6%)

0

0.0

(25.60 1.96–333.56)

Diastolic

0

2 (25%)

Heart rate

2.62 (0.78–8.81)

1.68 0.34–8.24)

7 (46.6%)

5 (62.5%)

Hemoglobin

2.83 (0.6–13.28)

3.31 (0.51–21.13)

3 (20%)

1 (12.5%)

Hematocrit

0.20 (0.04–0.91)

1.03E−009

3 (20%)

2 (25%)

PLT

0.28 (0.09–0.89)

0.35 (0.07–1.74)

TLC

7 (46.6%)

6 (75%)

561E+006

0.80 (0.04–13.44)

5 (33.3%)

2 (25%)

Co-infected patients were NS1 and RT-PCR positive for at least 2 serotypes and negative
for DENV neutralizing antibodies via PRNT. Patients with secondary infections were NS1
positive and positive for one serotype via RT-PCR and possessed DENV neutralizing
antibodies as determined by PRNT. Logistic analysis was performed in which co-infected
or secondary infections were compared against primary DENV infections. Bold font
indicates statistical significance. OR, odds ratio; CI, confidence interval; N, number
of patients.
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response to subsequent DENV infections as a result of their
antigenic cross-reactivity.
Another explanation may lie in the antigenic cross-reactivity
of the 4 serotypes. Antibody-dependent enhancement of
infection from prior exposures is accepted as the primary cause of
DHF, DSS, and death (2). However, recent work from Nicaragua
has shown that DENV antibodies can offer protection or
susceptibility to enhancement that is dependent on antibody titer
(51). Our data show that all four DENV serotypes continuously
circulate in Pakistan which could result in secondary infections
that occur during times when antibodies might offer protection
instead of enhancement. The same can be said for Haiti where all
4 serotypes continuously circulate (33). Clearly, more research is
warranted in this area.
This study used an orthogonal system of NS1 antigen
detection followed by RT-PCR for DENV detection and
subtyping. We were able to identify significantly more NS1
positive patients than RT-PCR likely due to the use of serum
as our RNA source. A growing body of research is showing
that recovery of viral RNA persists for much longer in urine,
saliva, whole blood, and plasma (52–54). Although we did
not perform any phylogenetic analysis, prior work has shown
that all four DENV serotypes circulating in Pakistan are
descendant from India (55). Interestingly, DENV emerged in
India during 1963, just 3 years prior to the Pakistan emergence
in 1966 (25, 56).
This study demonstrates that all 4 DENV serotypes are cocirculating and co-infecting in Pakistan. The data show that
each DENV serotype displayed at least one symptom at a
higher frequency than the other serotypes though unfortunately,
the incidence of specific symptoms was not discreet and was
identified at least once for all serotypes. However, if one applies
the clinical data to the system, one can generalize how each
serotype presents in febrile patients in Pakistan. DENV1 had the
greatest impact on the liver with higher frequency of abnormal
liver function tests; DENV2 affected the central nervous system
and joints; DENV3 affected the urinary system and blood;
and DENV4 caused headaches and rash. The ability of these
4 serotypes to occupy the same ecological niche has puzzled
scientists for decades. Perhaps the ability for specific serotypes to
preferentially infect specific cells contributes to their persistence
in the environment. These viruses provide an opportunity for
future studies in DENV pathogenesis.
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